RISK STRATIFICATION AND PATIENT COUNSELING FOR NATALIZUMAB IN MULTIPLE SCLEROSIS

被引：38
作者：
Fox, Robert J. [1 ]
Rudick, Richard A.
机构：
[1] Cleveland Clin, Mellen Ctr Multiple Sclerosis Treatment & Res, Dept Neurol, Cleveland, OH 44106 USA
来源：
NEUROLOGY | 2012年 / 78卷 / 06期
基金：
美国国家卫生研究院;
关键词：
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY;
D O I：
10.1212/WNL.0b013e318245d2d0
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：436 / 437
页数：2
相关论文
共 50 条
  • [21] Natalizumab for multiple sclerosis: the dilemma of NOVA
    Hellwig, Kerstin
    LANCET NEUROLOGY, 2022, 21 (07) : 579 - 581
  • [22] Natalizumab in the treatment of pediatric multiple sclerosis
    Talab, Radomir
    Talabova, Marika
    Klzo, Ludovit
    NEUROENDOCRINOLOGY LETTERS, 2012, 33 (06) : 579 - 589
  • [23] Natalizumab in multiple sclerosis: proceed with caution?
    Doggrell, Sheila A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2006, 7 (12) : 1675 - 1678
  • [24] Natalizumab for relapsing remitting multiple sclerosis
    Pucci, Eugenio
    Giuliani, Giorgio
    Solari, Alessandra
    Simi, Silvana
    Minozzi, Silvia
    Di Pietrantonj, Carlo
    Galea, Ian
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (10):
  • [25] Use of Natalizumab in Multiple Sclerosis Patients
    O'Connor, Paul W.
    CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2010, 37 (01) : 98 - 104
  • [26] Treatment of refractory epilepsy with natalizumab in a patient with multiple sclerosis. Case report
    Stefano Sotgiu
    Maria R Murrighile
    Gabriela Constantin
    BMC Neurology, 10
  • [27] Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads
    Prosperini, Luca
    Annovazzi, Pietro
    Capobianco, Marco
    Capra, Ruggero
    Buttari, Fabio
    Gasperini, Claudio
    Galgani, Simonetta
    Solaro, Claudio
    Centonze, Diego
    Bertolotto, Antonio
    Pozzilli, Carlo
    Ghezzi, Angelo
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 (13) : 1713 - 1722
  • [28] Natalizumab for multiple sclerosis: appraising risk versus benefit, a seemingly demanding tango
    Gupta, Sahil
    Weinstock-Guttman, Bianca
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2014, 14 (01) : 115 - 126
  • [29] PML in natalizumab-treated multiple sclerosis Modeling errors and risk miscalculations
    Mowry, Ellen M.
    McArthur, Justin C.
    NEUROLOGY, 2017, 88 (12) : 1110 - 1111
  • [30] First-line natalizumab in multiple sclerosis: rationale, patient selection, benefits and risks
    Nicholas, Jacqueline Ann
    Racke, Michael Karl
    Imitola, Jamie
    Boster, Aaron Lee
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2014, 5 (02) : 62 - 68
12345